Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy.

Liver international : official journal of the International Association for the Study of the Liver·2020
Same author

Tunable Mechanical Property and Structural Transition of Silicon Nitride Nanowires Induced by Focused Ion Beam Irradiation.

ACS applied materials & interfaces·2020
Same author

Advances on the in vivo and in vitro glycosylations of flavonoids.

Applied microbiology and biotechnology·2020
Same author

Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease.

American journal of physiology. Gastrointestinal and liver physiology·2020
Same author

Grading Solid Pseudopapillary Tumors of the Pancreas: the Fudan Prognostic Index.

Annals of surgical oncology·2020

Related Experiment Video

Updated: Jun 26, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.

Yuan Ji1, B Nebiyou Bekele

  • 1Department of Bioinformatics and Computational Biology, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Biometrics
|January 29, 2009
PubMed
Summary

This study introduces an outcome-adaptive randomization scheme for clinical trials, prioritizing treatments with better efficacy and lower toxicity. This patient-centered approach ensures more participants receive superior treatments, improving trial outcomes.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Medical Research

Background:

  • Comparative clinical trials often face challenges in balancing treatment allocation with patient benefit.
  • Joint efficacy and toxicity endpoints require sophisticated statistical modeling.

Purpose of the Study:

  • To develop an outcome-adaptive randomization (AR) scheme for clinical trials with joint efficacy/toxicity endpoints.
  • To favor treatments demonstrating superior efficacy and lower toxicity.
  • To enhance patient benefit by allocating more participants to better-performing treatments.

Main Methods:

  • Extended an approximate Bayesian time-to-event model to handle joint efficacy/toxicity outcomes.
  • Utilized a latent variable approach for posterior computation, accommodating incomplete patient follow-up.
  • Developed an AR scheme based on computed posterior probabilities favoring treatments with high efficacy and low toxicity.

Main Results:

  • The proposed AR scheme adaptively adjusts randomization probabilities.
  • The methodology effectively incorporates data from patients with incomplete follow-up.
  • Demonstrated application using a leukemia trial comparing three treatments based on remission and toxicity rates.

Conclusions:

  • The outcome-adaptive randomization scheme offers a patient-centered approach in clinical trials.
  • The statistical model provides a robust framework for joint efficacy/toxicity endpoints.
  • This method enhances trial efficiency and ethical considerations by favoring superior treatments.